Federation Des Caisses Desjardins Du Quebec Harrow Health, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $19 Billion
- Q1 2025
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Harrow Health, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 150 shares of HROW stock, worth $3,859. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150Holding current value
$3,859% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding HROW
# of Institutions
175Shares Held
21.1MCall Options Held
330KPut Options Held
670K-
Opaleye Management Inc. Boston, MA3.96MShares$102 Million28.93% of portfolio
-
Black Rock Inc. New York, NY2.15MShares$55.3 Million0.0% of portfolio
-
Private Capital Management, LLC Naples, FL1.89MShares$48.6 Million6.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.87MShares$48 Million0.0% of portfolio
-
Braidwell LP Stamford, CT957KShares$24.6 Million1.56% of portfolio
About HARROW HEALTH, INC.
- Ticker HROW
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 27,070,000
- Market Cap $697M
- Description
- Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...